Cancer Targeted Therapy

AKT Kinase Inhibitor hydrochloride (Standard) is the analytical standard of AKT Kinase Inhibitor hydrochloride (HY-10249D). This product is intended for research and analytical applications. AKT Kinase Inhibitor hydrochloride is an Akt kinase inhibitor with anti-tumor activity. AKT Kinase Inhibitor hydrochloride is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

tert-Butyl 4-(4-aminophenoxy)piperidine-1-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.

(R)-Boc-4-NH2-3,3-difluoropiperidin is a PROTAC linker that can be used in the synthesis of PROTACs.

CU-CPT22 (Standard) is the analytical standard of CU-CPT22 (HY-108471). This product is intended for research and analytical applications. CU-CPT22 is a potent protein complex of toll-like receptor 1 and 2 (TLR1/2) inhibitor, and competes with the synthetic triacylated lipoprotein (Pam3CSK4) binding to TLR1/2 with a K_i of 0.41 µM. CU-CPT22 blocks Pam3CSK4-induced TLR1/2 activation with an IC₅₀ of 0.58 µM.

(S,R,S)-AHPC-PEG2-NH2 hydrochloride (Standard) is the analytical standard of (S,R,S)-AHPC-PEG2-NH2 hydrochloride (HY-103603). This product is intended for research and analytical applications. (S,R,S)-AHPC-PEG2-NH2 hydrochloride (VH032-PEG2-NH2 hydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.

Cy3 labled MDM4-targeting ASO sodium is a Cy3 labled MDM4-targeting ASO sodium.

CRBN ligand-262 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. CRBN ligand-262 can be linked to a target protein ligand via a linker to form a PROTAC.

Eratrectinib (Example 1) is a Trk inhibitor. Eratrectinib can be studied in research for tropomyosin receptor kinase-related diseases and cancers.

NIBR-17 is a pan-class I PI3K inhibitor with suitable pharmacokinetic properties and inhibits tumor growth.

GDC-0575-d₄ (ARRY-575-d₄) is the deuterium labeled GDC-0575 (HY-112167). GDC-0575 (ARRY-575, RG7741) is a highly-selective oral small-molecule Chk1 inhibitor with an IC₅₀ of 1.2 nM.

TM5007 is a poent and orally active inhibitor of plasminogen activator inhibitor-1 (PAI-1) with an IC₅₀ of 29 μM. TM5007 enhance fibrinolysis activity and inhibits coagulation. TM5007 also prevents the fibrotic process initiated by bleomycin in mouse lung.

VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent VEGFR-2 inhibitor with an IC₅₀ of 0.037 µM. VEGFR-2-IN-12 shows high growth inhibition against MCF-7 cells (GI₅₀=1.6 µM). VEGFR-2-IN-12 has antitumor activity.

PI3Kδ-IN-5 (compound 7n) is a highly potent and selective inhibitor of PI3Kδ with an IC₅₀ of 0.9 nM.

Exatecan Intermediate 1-d₂ is the deuterium labeled Exatecan Intermediate 1 (HY-42487). Exatecan Intermediate 1 (compound 6) is an intermediate of Exatecan (HY-13631). Exatecan is a DNA topoisomerase I inhibitor with anticancer effects.

Metformin-¹³C₂ (1,1-Dimethylbiguanide-¹³C₂) hydrochloride is the ¹³C-labeled Metformin hydrochloride (HY-17471A). Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo.

Pirarubicin (Hydrochloride) (Standard) is the analytical standard of Pirarubicin (Hydrochloride). This product is intended for research and analytical applications. Pirarubicin Hydrochloride is an anthracycline antibiotics, acts as a topoisomerase II inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors.

(rac)-Etodolac-d₃ is a labelled racemic Etodolac. Etodolac (AY-24236) is a non-steroidal anti-inflammatory compound that is a non-selective inhibitor of COX (IC50=53.5 nM)

Tuvusertib-d₃ (M1774-d₃) is the deuterium labeled Tuvusertib (HY-111451). Tuvusertib (M1774; ATR inhibitor 1) is a selective and orally active ATR inhibitor with a K_i value below 1 μΜ.

LDC0496 is a potent and selective EGFR inhibitor. LDC0496 possesses intense inhibitory potency toward EGFR and Her2 exon20 insertion mutations, as well as selectivity over wild type EGFR and within the kinome.

Luvometinib-d (FCN-159-d) is the deuterated-labeled Luvometinib (HY-159846). Luvometinib is an orally potent MEK1/2 inhibitor. Luvometinib selectively blocks the MAPK signaling pathway by forming a ternary complex with MEKase and ATP, thereby reducing the phosphorylation level of ERK. Luvometinib induces cell cycle arrest and apoptosis, and inhibits cancer cell proliferation. Luvometinib can be used in relevant research on various solid tumors including melanoma, non-small cell lung cancer, colon cancer, and acute myeloid leukemia.